@StoneEL2

#PhD #Tcells #Immunotherapy #TumorImmunity #Immunology Tweets are my opinion, retweets not endorsement. Recovering academic. she/her. Now design Next-Gen CPIs.

 San Francisco, CA
Joined June 2018
  • Tweets5K
  • Following4K
  • Followers2.3K
56Media
Dr. E. L. Stone retweeted
Dr. E. L. Stone@StoneEL2Apr 22
I was delighted to help reveal the first clinical data for GIGA-564, a differentiated, non-blocking anti-CTLA-4 mAb designed to selectively deplete intratumoral Tregs.
1
1
10
222
Dr. E. L. Stone retweeted
Sergio Quezada@squezadd21 May 2024
Absolutely honoured to be elected Fellow of the Academy of Medical Sciences together with amazing ⁦@ucl⁩ colleagues!! Thanks to ⁦⁦@uclcancer⁩ ⁦@CR_UK⁩ and my amazing team ⁦@QuezadaLab⁩ ucl.ac.uk/news/2024/may/ucl-…

UCL academics elected to Academy of Medical Sciences | UCL News

Four UCL scientists have been elected Fellows of the Academy of Medical Sciences in recognition of their exceptional contributions to the study of rheumatology, neurobiology, immunotherapy and...

ucl.ac.uk
14
12
2
102
6,125
Congrats to Drs. Mark Rubinstien and John Wrangle for clinical work with IL15 synthetic cytokine and PD1 therapy for lung cancer.
MUSC Hollings Cancer Center@muschollings22 Nov 2022
"It's a whole new era for lung cancer," says oncologist Dr. John Wrangle. Scientists are working to develop new, targeted treatments for lung cancer. Hear all about the latest developments on this episode of Hollings Cross Talk. youtu.be/OMrMs8LZWFo

Cross Talk: Lung Cancer

"It's a whole new era for lung cancer," says oncologist Dr. John Wr...

youtube.com
1
1
1
10
Dr. E. L. Stone retweeted
Bill Sullivan@wjsullivan18 Nov 2022
Elon, please buy the NRA next
3
27
I know smart people like #MarkRubinstein from ⁦@OhioStatePIIO⁩ !
1
2
25
Dr. E. L. Stone retweeted
Adrian Liston@LabListon14 Nov 2022
For anyone doing #flowcytometry, would you like to have a new protocol that reduces your #antibody costs by ~10-fold and also gives you higher quality data, with better signal-to-noise ratio? Yes? Then read work by @olivertburton and @CarlyEWhyte. 1/6 currentprotocols.onlinelibra…
36
316
42
1,110
So incredibly thankful to be a part of this group. Spending time networking and learning with my fellow Sparkies this week has been the best start to #SITC22 @sitcancer
Michelle Williams, PhD@mwilli32310 Nov 2022
It’s been an amazing week @sitcancerECS @sitcancer #SITC22 pre-conference and conference events catching up with Sparkathon members and alumni! Congrats again to the Class of 2022!
2
13
Awesome talk by Dr. @Chrystal_Paulos at the Winship Scientific Symposium!! @WinshipAtEmory @PaulosLab
2
1
14
Cheers to ⁦Hannah Knochelmann ⁦@hknochelmann⁩ for first place at the Perry Hallushka Research Day ⁦@muschollings⁩ ⁦@MedUnivSC⁩!
1
9
Dr. E. L. Stone retweeted
Ruth Shouval@shouval1 Nov 2022
Second 🌟New 🌟Paper alert 🥳! Told you September was a good month in the @shouval_lab 😌 : Our study on how BRCA mutational status shapes CAFs in PDAC is out in @NatureComms : nature.com/articles/s41467-0… 1/8

BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin...

Nature Communications - Cancer-associated fibroblasts are transcriptionally rewired by signals from the cancer cells, resulting in heterogeneous populations. Here the authors show that loss of BRCA...

nature.com
32
42
8
276
So happy to see this out in the world 🌎 Congrats, @MeganMWyatt, @Chrystal_Paulos and team! Huge implications for how we manufacture CAR-T for the clinic.
Chrystal Paulos@Chrystal_Paulos1 Nov 2022
💥Less is more: @MeganMWyatt’s new manuscript in @biorxivpreprint shows metabolically fit CAR T cells can be generated using fewer activation beads in @PaulosLab w/ @LesinskiLab @ImmuneCellsRUs. Props @GuillermoORang1 @hknochelmann @nelson_CD26 @Aubrey_Smith04 @WinshipAtEmory
2
7
Dr. E. L. Stone retweeted
Weitzman Lab@WeitzmanLab28 Oct 2022
It's a beautiful day in the City of Brotherly Love with early morning sun caught on the CHOP/Penn buildings. Our lab has open positions at all levels (techs, students, postdocs & more). DM me for opportunities to work on viruses and cell biology. Come join us! @CHOP @Penn
2
40
7
137
Dr. E. L. Stone retweeted
Robin Reschke@DrRobinReschke22 Oct 2022
Impressive tour de force from @RZappasodi on how to leverage tumor metabolism for improved anti-tumor immunity. In glycolysis low tumors Tregs produce Th1 cytokines such as IFNg when treated with anti-CTLA4. Super cool work 😍 #AACRtii22
2
12
Dr. E. L. Stone retweeted
Robin Reschke@DrRobinReschke23 Oct 2022
Diet suggestions for an anti tumor fiber-rich diet from the legendary @JenWargoMD given in another excellent talk 🍎 #AACRtii22
6
1
28
Dr. E. L. Stone retweeted
Jeff Rathmell@JeffRathmell21 Oct 2022
⁦The star of the ⁦@VUMC_VCI⁩ retreat ⁦@Chrystal_Paulos⁩
2
23
Tregs go away w agonistic aCD40 tx, but where do they go? Neighbor extraordinaire Kate Byrne @OHSUKnight, Ron Germain and team show that they convert into type I effector cells in the pancreatic TME. Check it out! biorxiv.org/content/10.1101/…

Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environment

Multiple cell types, molecules, and processes contribute to inhibition of anti-tumor effector responses, often frustrating effective immunotherapy. Among these, Foxp3+ CD4+ cells (Tregs) are well-r...

biorxiv.org
2
5
34
Dr. E. L. Stone retweeted
Igor Brodsky@BrodskyIgor12 Oct 2022
Thrilled to announce two openings for tenure track faculty positions in the Department of Pathobiology @pennvet. Come join our vibrant, dynamic, innovative research community of outstanding colleagues and mentors. Apply here: apply.interfolio.com/115308.
1
118
6
164
Academia to women in academia.....
37
1,400
151
13,243
Dr. E. L. Stone retweeted
Stanford University
@Stanford5 Oct 2022
“I’m the same person I was at 1 a.m., but I’m realizing that my voice now has a platform, and I’m thinking about how to use that.” -@CarolynBertozzi, winner of the 2022 #NobelPrize in chemistry 🗞: stanford.io/3C92ELW
26
497
71
5,104
Dr. E. L. Stone retweeted
Academic Exit@academic_exit3 Oct 2022
PhDs: is your advisor actively helping you get a tenure-track job? If not, you're at a disadvantage relative to others in the market. Many PIs actively sponsor their students through the networks that they have built; others don't. (sharing b/c I learned this too late)
43
177
41
1,753
Load more